Phase 3 trial demonstrates improved overall survival in early-stage triple-negative breast cancer with pembrolizumab, highlighting lasting benefits.
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition of pembrolizumab to platinum-containing chemotherapy. Here we report the final results for overall survival.
No takes yet. Share an insight, caveat, or question.
Schmid et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: